A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

NCT06140524 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

116

Enrollment

INDUSTRY

Sponsor class

Conditions

Monoclonal Gammopathy of Undetermined Significance (MGUS)
Smoldering Multiple Myeloma (SMM)

Interventions

DRUG: Linvoseltamab

Sponsor

Regeneron Pharmaceuticals